CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.430
EU - Europa 9.265
AS - Asia 7.418
SA - Sud America 939
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 10
Totale 31.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.334
GB - Regno Unito 3.680
SG - Singapore 3.599
CN - Cina 2.583
FR - Francia 1.087
DE - Germania 844
BR - Brasile 842
IE - Irlanda 781
RU - Federazione Russa 769
SE - Svezia 695
HK - Hong Kong 623
FI - Finlandia 525
IT - Italia 510
KR - Corea 173
UA - Ucraina 169
TR - Turchia 93
VN - Vietnam 87
CA - Canada 60
IN - India 49
AR - Argentina 38
JP - Giappone 37
PL - Polonia 37
BD - Bangladesh 35
AT - Austria 29
ES - Italia 24
BE - Belgio 23
ZA - Sudafrica 21
NL - Olanda 20
IQ - Iraq 16
MX - Messico 15
UZ - Uzbekistan 15
EC - Ecuador 14
TN - Tunisia 13
ID - Indonesia 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
MA - Marocco 10
PE - Perù 10
PK - Pakistan 10
AZ - Azerbaigian 9
EU - Europa 9
LT - Lituania 9
CO - Colombia 8
PS - Palestinian Territory 8
SA - Arabia Saudita 8
AU - Australia 7
EG - Egitto 7
KE - Kenya 7
VE - Venezuela 7
BG - Bulgaria 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
PT - Portogallo 6
RO - Romania 6
SN - Senegal 6
CH - Svizzera 5
GA - Gabon 5
GR - Grecia 5
IL - Israele 5
KG - Kirghizistan 5
MD - Moldavia 5
PY - Paraguay 5
UY - Uruguay 5
HU - Ungheria 4
IR - Iran 4
JO - Giordania 4
NO - Norvegia 4
NP - Nepal 4
PA - Panama 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
HR - Croazia 2
JM - Giamaica 2
NI - Nicaragua 2
OM - Oman 2
PH - Filippine 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BT - Bhutan 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
Totale 31.145
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Jacksonville 2.515
Singapore 1.870
Woodbridge 1.526
Chandler 1.414
Ann Arbor 934
Dallas 923
Houston 826
Ashburn 813
Dublin 781
Hong Kong 618
Wilmington 418
Lawrence 372
Princeton 371
Lancaster 356
Nanjing 301
Jinan 274
Sindelfingen 262
Shenyang 219
Beijing 202
New York 188
Los Angeles 170
Buffalo 150
Kent 149
The Dalles 149
Hebei 145
Changsha 120
Tianjin 111
Zhengzhou 103
Boardman 97
Haikou 91
Nanchang 90
Milan 87
Helsinki 78
Taizhou 75
Verona 74
Jiaxing 72
Columbus 71
Guangzhou 69
Hangzhou 69
Ningbo 68
São Paulo 65
Taiyuan 61
Norwalk 50
Washington 47
Moscow 46
Santa Clara 46
Redondo Beach 44
Munich 43
Falls Church 42
Seattle 42
Lanzhou 40
Nuremberg 34
Tokyo 33
Ho Chi Minh City 32
Chicago 30
Council Bluffs 28
Philadelphia 28
San Francisco 27
Rio de Janeiro 25
Brooklyn 24
Seoul 23
Fuzhou 22
Belo Horizonte 21
Toronto 21
Warsaw 21
Brussels 20
Hanoi 20
Stockholm 20
Boston 19
Auburn Hills 18
Turku 18
Rome 15
Tashkent 15
Porto Alegre 14
Brasília 13
Dearborn 13
Fairfield 13
Atlanta 12
Goiânia 12
Phoenix 12
Vienna 12
Dhaka 11
Mehlingen 11
Qingdao 11
Redwood City 11
Amsterdam 10
Chennai 10
Curitiba 10
Edinburgh 10
Frankfurt am Main 10
Johannesburg 10
Montreal 10
Salvador 10
Tappahannock 10
Baku 9
Charlotte 9
San Mateo 9
Serra 9
Shanghai 9
Totale 21.482
Salva come PNG Salva come JPEG
Nome #
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 288
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 232
La regressione della cirrosi epatica: non più un mito. 161
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 157
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 147
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 145
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 143
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 141
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 136
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 136
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 135
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 135
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 134
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 132
Malattie autoimmuni del fegato 130
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 130
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 127
[Infection due to hepatitis B virus and host immune response] 126
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 125
A long term study of hepatitis G virus coinfection in chronic hepatitis B 124
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 124
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 124
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 123
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 121
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 120
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 119
Suppressor cell function in chronic active hepatitis 119
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 119
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 119
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 118
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 116
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 116
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 115
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 114
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 114
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 113
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 112
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 112
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 112
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 110
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 110
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 109
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 109
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 108
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 108
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 107
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 106
Clinical and virological profiles in patients with multiple hepatitis virus infections. 106
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 106
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 106
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 106
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 106
Incidenza e fattori di rischio di epatocarcinoma. 105
Natural history of hepatitis B and prognostic factors of disease progression 105
Natural history of chronic hepatitis B 105
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 105
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 105
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 104
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 104
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 104
Natural course and prognostic factors of hepatitis B. 104
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 104
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 104
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 103
Morbidity and mortality in compensated cirrhosis type C: relationship to interferon alpha therapy 103
Natural history of HBV and HDV infection and liver disease 103
Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection 103
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 103
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 102
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 102
T and K cell function in acute and chronic hepatitis 102
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 102
Hepatitis C virus genotype and clinical outcome of compensated cirrhosis type C 101
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 101
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 101
Cellular immunity to the hepatitis B virion in acute and chronic infection 101
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 101
Interferon therapy for the anti-HBe positive form of chronic hepatitis B 100
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 100
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 100
Virus replication and liver disease in chronic hepatitis B virus infection 100
Hepatitis C and cirrhosis 100
Long term outcome in HBeAg positive cirrhosis treated with interferon alpha: relation between ALT normalization and survival 100
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 100
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 99
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 99
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 99
Chronic persistent hepatitis type B can be a progressive disease when associated with sustained virus replication. 99
Effects of interferon plus ribavirin treatment on NF-kB, TGF-b1 and metalloproteinase activity in patients with chronic hepatits C: an in vivo immunohistochemical study 99
Natural history of hepatitis B virus infection and disease 99
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 99
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 98
Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. 98
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. 98
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 98
IL28B genotype, differential expression of intrahepatis interferon-stimulated genes and response to PEG-IFN and ribavirin therapy in an Italian prospective cohort of genotype 1 hepatitis C patients in “real life”. 98
Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy 97
HLA-DR expression in liver in human HIV infection 97
Delayed clearance of serum HBAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis 97
Reduced serum hepcidin levels in patients with chronic hepatitis C 97
Totale 11.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.226
article - articoli 46.822
book - libri 0
conference - conferenze 50.523
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 9.881
Totale 214.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.905 0 0 0 309 367 260 16 359 152 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/20263.073 1.307 709 942 115 0 0 0 0 0 0 0 0
Totale 31.233